Honestly Meirluc,
I believe that much will depend on how the media responds to a UK approval, and how the company treats it. If we get substantial media coverage, and if LP and others make appearances at Institutional and Brokerage conferences, etc and investors are being well informed about the advancements the company is making, we should skyrocket.
On the other had if coverage is mediocre, and if the company just keeps working, but doesn't tell the world what it's planning to do, then the bashers can hold down the share price growth, at least for awhile. Don't get me wrong, we should be in the $2 or so range, but claims from bashers like, the FDA will never approve, will stick unless the company has given us a plan for approaching the FDA. I'm fine with it not happening until the EDEN is approved, I'd just like to see that's the official position, if that's what it is.
Clearly I hope the company comes out swinging when UK approval comes, but I realize that the regulators abhor hype, so they need to be professional in their approach. I believe that they can get, or pay for, making presentations at conferences that gets the word out to the investment public. Many years ago, when IMGN was in its infancy, they'd routinely appear in BIO Conferences, I believe they paid to webcast from there, but it kept investors informed. I believe the company will pick up analysts, but they must webcast quarterlies and permit them to ask questions. In short, whether they can immediately upgrade to a major exchange, or not, they need to act the way they'd be expected to if they were on a major exchange. If they hold up in their shell, then the bashers can hold us down until more approvals actually occur, rather than in anticipation of what the company says will be happening as we advance into the future.
Gary
